Patent ID: 7645736

Claim:
A method for treatment of a disease of the eye of a patient resulting from angiogenesis and neovascularization in the eye comprising injecting into the vitreous body of the eye of said patient a composition comprising a therapeutically effective mount of an α v β 3 and/or α v β 5 inhibitor sufficient to inhibit angiogenesis and inhibit neovascularization in the treated eye, wherein the α v β 3 and/or α v β 5 inhibitor is a compound of formula II: wherein R 1 is H, alkyl having 1-6 C atoms or benzyl, R 2 is R 10 , CO—R 10 , COOR 6 , COOR 10 , SO 2 R 6 or SO 2 R 10 , R 3 is H, Hal, OA, NHR 10 , N(R 10 ) 2 , —NH-acyl, —O-acyl, CN, NO 2 , OR 10 , SR 10 , R 2 or CONHR 10 , R 4 is H, ═O, ═S, C 1 -C 6 -alkyl or acyl, R 5 is NH 2 , H 2 N—C(═NH) or H 2 N—(C═NH)—NH, where the primary amino groups are optionally provided with conventional amino protective groups and optionally mono-, di- or tri-substituted by R 10 , CO—R 10 , COOR 10 or SO 2 R 10 , or R 6 , R 7 , R 8 are each independently of one another absent or H, or R 7 and R 8 together are a bond, X, Y are each independently of one another ═N—, —N—, O, S, —CH 2 — or ═C—, with the proviso that at least one of X and Y is ═N—, —N—, O or S, W, Z are each independently of one another absent, O, S, NR 1 , C(═O), CONH, NHCO, C(═S)NH, NHC(═S), C(═S), SO 2 NH, NHSO 2 or CA═CA′, R 6 is a mono- or binuclear heterocycle which has 1 to 4 N, O and/or S atoms and is unsubstituted or mono-, di- or tri-substituted by Hal, A, —CO—A, OH, CN, COOH, COOA, CONH 2 , NO 2 , ═NH or ═O, R 9 is H, Hal, OA, NHA, NAA′, NHacyl, Oacyl, CN, NO 2 , SA, SOA, SO 2 A, SO 2 Ar or SO 3 H, R 10 is H, A, Ar or aralkyl having 7-14 C atoms, R 11 is H or alkyl having 1-6 C atoms, A, A′ are each independently of one another H or unsubstituted or mono-, di- or tri-R 9 -substituted alkyl or cycloalkyl, each of which has 1-15 C atoms and in which one, two or three methylene groups can be replaced by N, O and/or S, Ar is unsubstituted or mono-, di- or tri-A- and/or R 9 -substituted mono- or binuclear aromatic ring system having 0, 1, 2, 3 or 4 N, O and/or S atoms, Hal is F, Cl, Br or I and m, n are each independently of one another 0, 1, 2, 3 or 4; or a physiologically acceptable salt thereof.